Galmed Pharmaceuticals (GLMD) announced positive preliminary results from Part 1 of the Ph1 Bioavailability AM-001 Study of Aramchol Meglumine. The company said initial findings suggest that the new Aramchol Meglumine formulation offers higher bioavailability than Aramchol free acid and that a once-daily, oral 200 mg dose is likely to be optimal for future trials.
Previously, the FDA approved the transition from Aramchol acid to Aramchol Meglumine under a new IND. The requirement for this transition was a bioavailability study to compare the two formulations. The AM-001 study was conducted in response to that FDA request. Part 2 of the study is anticipated to conclude in the second half of 2025.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.